Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWGilvocarcin M is an antibiotic originally isolated from S. gilvotanareus.1 It is active against S. aureus when used at a concentration of 32 µg/ml.2 Gilvocarcin M inhibits growth of KB cells (IC50 = 0.52 µg/ml) but has no effect on survival in a P388 mouse model of leukemia when used at doses ranging from 25 to 400 mg/kg.3 Gilvocarcin M intercalates into bacteriophage PM2 DNA.4 It is toxic to rats with an intravenous LD50 value of 450 mg/kg.3
WARNING This product is not for human or veterinary use.
1. Gilvocarcins, new antitumor antibiotics. 1. Taxonomy, fermentation, isolation and biological activities. J. Antibiot. (Tokyo) 34(3), 266-270 (1981).
2. Antitumor agents from Streptomyces anandii: gilvocarcins V, M and E. J. Antibiot. (Tokyo) 34(12), 1544-1555 (1981).
3. Gilvocarcins, new antitumor antibiotics. 3. Antitumor activity. J. Antibiot. (Tokyo) 34(6), 701-707 (1981).
4. Gilvocarcins, new antitumor antibiotics. 4. Mode of action. J. Antibiot. (Tokyo) 35(8), 1038-1041 (1982).